Indications：
Lenvatinib is a kinase inhibitor indicated for:Differentiated Thyroid Cancer (DTC)
- The treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma (RCC)
- In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
Hepatocellular Carcinoma (HCC)
- The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Cancer (EC)
- In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
Dosage and AdministrationMonotherapy:
- DTC: Recommended dose is 24 mg orally once daily.
- HCC: Recommended dose is based on actual body weight:
- Patients ≥ 60 kg: 12 mg orally once daily.
- Patients < 60 kg: 8 mg orally once daily.
Combination Therapy:
- EC: Recommended dose is 20 mg orally once daily in combination with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
- RCC: Recommended dose is:
- 20 mg orally once daily in combination with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
- 18 mg orally once daily in combination with everolimus 5 mg.
Dose modifications are recommended for patients with renal or hepatic impairment.
Specification：
4 mg per capsule, 30 capsules per box.
4 mg per capsule, 30 capsules per box.
Reviews
There are no reviews yet.